Neurocrine Biosciences presented two-year Phase 3 data showing CRENESSITY (crinecerfont) effectively controls excess androgens and reduces glucocorticoid doses in children with classic congenital adrenal hyperplasia (CAH). The treatment led to sustained hormone improvements, including reductions in ACTH and 17-hydroxyprogesterone, and clinical benefits such as improved body mass index and insulin resistance. These results suggest CRENESSITY may improve long-term health outcomes and quality of life for pediatric CAH patients by enabling lower steroid doses and better hormonal balance. The findings build on earlier data and support CRENESSITY's role in redefining CAH treatment.
VYKAT XR (diazoxide choline) treatment demonstrated significant and lasting improvements in hyperphagia and behavioral symptoms in individuals with Prader-Willi syndrome (PWS) for up to three years. Participants who resumed VYKAT XR after a 16-week w...
Neurocrine Biosciences reported that CRENESSITY (crinecerfont) significantly improved hormone levels and reduced glucocorticoid doses in patients with classic congenital adrenal hyperplasia (CAH) due to 11β-hydroxylase deficiency, a rare form of CAH....
Neurocrine Biosciences announced two-year Phase 3 data from the CAHtalyst Pediatric study showing that CRENESSITY (crinecerfont) treatment slows bone age progression and improves predicted adult height in children with classic congenital adrenal hype...
Neurocrine Biosciences announced that two-year data from their Phase 3 CAHtalyst Adult study shows CRENESSITY (crinecerfont) improves cardiometabolic outcomes like insulin resistance, body weight, and bone health in adults with classic congenital adr...
